Multivessel Disease Patients’ Outcome and Second Generation Stent: Is Syntax Still a Valid Score? A RealWorld Study from a Tertiary Center

Authors

  • Cristina Giglioli Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Niccolò Marchionni Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Alessio Mattesini Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Chiara Zocchi Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Manuel Biagioli Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Marco Chiostri Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Salvatore Mario Romano Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence
  • Emanuele Cecchi Department of Cardiovascular and Thoracic Medicine, Azienda Ospedaliero-Universitaria Careggi, Florence

DOI:

https://doi.org/10.5644/ama2006-124.316

Keywords:

Multivessel Disease, Percutaneous Coronary Intervention, SYNTAX Trial, Dual Antiplatelet Therapy, Outcome

Abstract

Objective. The SYNTAX trial was designed to evaluate whether multivessel disease patients could benefit from percutaneous or surgical revascularization using a paclitaxel eluting stents, but after the introduction of second generation stents, this score needs to be reevaluated. The aim of our study was to analyze the association between SYNTAX score and the prognosis of mul­tivessel patients submitted to percutaneous coronary intervention (PCI) and second generation everolimus eluting stents (EES) implantation.

Materials and Methods. Data on 289 patients with multivessel coronary artery disease submitted to PCI with EES were stored in a dedicated database and retrospectively analyzed. During a mean follow-up period of 14.4±6.4 months, major adverse cardiac and cerebrovascular events (MACCE) including death from any cause, myocardial infarction, target lesion revascularization (TLR) and stroke, were systematically assessed.

Results. The incidence of MACCE at follow-up was 13.1%; death from any cause occurred in 19 patients (6.6%) and myocardial infarction in 9 patients (3.1%). TLR was detected in 2.7% of patients and stroke was observed in 2 patients. The SYNTAX score did not prove to be an independent predictor of overall death at multivariable analysis.

Conclusion. At mid-term follow-up, the incidence of MACCE in multivessel disease patients submit­ted to PCI and EES implantation was low; no significant association was found between SYNTAX score severity and MACCE at follow-up, suggesting that it should be modified after the introduction of EES.

Downloads

Download data is not yet available.

Downloads

Published

2021-03-12

How to Cite

Giglioli, C., Marchionni, N., Mattesini, A., Zocchi, C., Biagioli, M., Chiostri, M., Romano, S. M., & Cecchi, E. (2021). Multivessel Disease Patients’ Outcome and Second Generation Stent: Is Syntax Still a Valid Score? A RealWorld Study from a Tertiary Center. Acta Medica Academica, 49(3), 265–277. https://doi.org/10.5644/ama2006-124.316

Issue

Section

Clinical Science

Most read articles by the same author(s)

Similar Articles

You may also start an advanced similarity search for this article.